Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer

Documenti analoghi

• A brand new era of cancer immunotherapy: breakthroughs and challenges
  di: Bai, Ri-Lan, et al.
  Pubblicazione: (2021)
• Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids
  di: Sun, Lejia, et al.
  Pubblicazione: (2019)
• Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment
  di: Krieger, Tina, et al.
  Pubblicazione: (2020)
• Programmed cell death-1/programmed cell death-ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages
  di: Jia, Lingling, et al.
  Pubblicazione: (2021)
• Cost‐effectiveness analysis of first‐line treatments for advanced epidermal growth factor receptor‐mutant non‐small cell lung cancer patients
  di: Li, Wen‐Qian, et al.
  Pubblicazione: (2021)